Salivary gland cancer

Salivary gland cancer is a malignant tumor arising from the major or minor salivary glands located in the head and neck region. The major salivary glands include:

• Parotid glands.

• Submandibular glands.

• Sublingual glands.

Minor salivary glands are distributed throughout the mucosal surfaces of the upper aerodigestive tract.

Salivary gland cancers comprise a diverse group of tumors with different biological behaviors. The most common malignant salivary gland tumors include:

• Mucoepidermoid carcinoma.

• Adenocarcinoma.

Clinical presentation varies depending on the anatomical site involved, tumor type, and extent of disease.

Epidemiology

Salivary gland cancers are relatively uncommon compared with other head and neck malignancies. They may occur in both major and minor salivary glands and affect individuals across different age groups.

The clinical behavior ranges from slow-growing localized tumors to aggressive malignancies with local invasion, lymph node involvement, and distant metastasis.

Risk factors

Risk factors associated with salivary gland cancer include:

• Increasing age.

• Previous radiation exposure to the head and neck region.

• Occupational exposure to certain carcinogens.

• Genetic predisposition.

• Chronic inflammatory conditions of salivary glands.

Pathophysiology

Salivary gland cancer develops due to malignant transformation of glandular epithelial cells.

The process involves:

• Abnormal cellular growth.

• Formation of malignant glandular tumors.

• Local invasion of surrounding tissues.

• Involvement of nearby nerves causing neurological symptoms.

• Regional lymphatic spread to cervical lymph nodes.

• Distant metastasis in advanced disease.

Tumor behavior depends on the histological subtype and grade of malignancy.

Clinical presentation

Presentation depends on:

• Primary site involved.

• Tumor histological type.

• Tumor grade.

• Presence of local or metastatic spread.

The most common presentations are related to a growing mass, pain, and nerve involvement.

Symptoms

Common symptoms include:

• Salivary gland mass.

• Pain in the affected region.

• Neck mass.

• Facial or other nerve-related symptoms.

• Difficulty with movement of involved structures due to nerve involvement.

Clinical signs

Clinical findings may include:

• Palpable salivary gland swelling.

• Firm or irregular gland mass.

• Cervical lymphadenopathy.

• Cranial nerve palsies.

• Features of local invasion.

Differential diagnosis

Conditions that may mimic salivary gland cancer include:

• Benign salivary gland tumors.

• Chronic sialadenitis.

• Salivary gland cysts.

• Lymphoma.

• Metastatic lymph node disease.

• Abscess of salivary glands.

Diagnostic criteria

Salivary gland cancer should be suspected in patients presenting with:

• Persistent salivary gland mass.

• Progressive enlargement of gland swelling.

• Pain associated with a gland mass.

• Nerve palsies.

• Cervical lymph node enlargement.

Definitive diagnosis requires histopathological confirmation from biopsy.

Investigations

Laboratory investigations

• Full blood count (FBC).

• Liver function tests (LFT).

• Renal function tests (RFT).

Imaging investigations

• Chest X-ray (CXR).

• Computed tomography (CT) scan of the head and neck.

• Magnetic resonance imaging (MRI) of the head and neck.

Imaging helps assess:

• Primary tumor extent.

• Local invasion.

• Regional lymph node involvement.

• Resectability.

Histopathological investigation

• Biopsy of the primary tumor for histology.

Histological examination determines:

• Tumor type.

• Tumor grade.

• Treatment planning.

Diagnostic staging

Salivary gland cancer is staged using:

• TNM staging system.

Management

Management depends on:

• Tumor site.

• Histological type.

• Tumor grade.

• Disease stage.

• Resectability.

• Presence of lymph node involvement.

Treatment requires a multidisciplinary approach involving:

• Head and neck surgeons.

• Radiation oncologists.

• Medical oncologists.

• Pathologists.

• Radiologists.

Non-pharmacological treatment

Surgery

Complete surgical resection is the primary treatment for resectable salivary gland cancer.

The aim of surgery is:

• Complete removal of the primary tumor.

• Achievement of clear surgical margins.

• Assessment and management of regional lymph nodes when indicated.

Adjuvant radiotherapy

Adjuvant radiotherapy is indicated after surgery when adverse features are present, including:

• High-risk tumor characteristics.

• Incomplete surgical clearance.

• Other pathological risk factors.

Management of unresectable disease

For patients whose disease is not surgically resectable:

• Definitive radiotherapy may be used.

OR

• Concurrent chemoradiotherapy may be indicated.

Neck dissection

Neck dissection is indicated in:

• High-grade tumors.

• Clinically positive neck disease.

Pharmacological treatment

(No chemotherapy drugs or specific dosing schedules were provided in the source information; therefore, no additional drug regimens are added.)

Chemotherapy may be considered as part of concurrent chemoradiotherapy or advanced disease management according to specialist oncology assessment.

Management according to disease stage

Resectable disease

Management:

• Complete surgical resection.

Followed by:

• Adjuvant radiotherapy if adverse features are present.

High-grade tumors or clinically positive neck disease

Management:

• Surgical resection.

• Neck dissection.

Additional treatment:

• Adjuvant radiotherapy when indicated.

Unresectable disease

Management:

• Definitive radiotherapy.

OR

• Concurrent chemoradiotherapy.

Referral

All patients with suspected or confirmed salivary gland cancer should be referred to a specialized head and neck oncology center for:

• Histological confirmation.

• TNM staging.

• Surgical evaluation.

• Multidisciplinary treatment planning.

Urgent referral is required for:

• Rapidly growing salivary gland masses.

• Painful gland swelling.

• Nerve palsies.

• Neck masses.

Complications

Complications may include:

• Facial or cranial nerve dysfunction.

• Local invasion.

• Cervical lymph node metastasis.

• Distant metastasis.

• Recurrence.

• Functional impairment after treatment.

• Cosmetic complications following surgery.

Prognosis

Prognosis depends on:

• Tumor histological type.

• Tumor grade.

• Disease stage.

• Presence of lymph node involvement.

• Completeness of surgical resection.

• Response to radiotherapy.

Low-grade localized tumors generally have better outcomes, while high-grade and advanced tumors have poorer prognosis.

Prevention

Preventive strategies include:

• Avoidance of unnecessary radiation exposure.

• Occupational protection from carcinogenic exposures.

• Early assessment of persistent salivary gland swellings.

• Prompt referral of suspicious lesions.

Follow-up

Patients require regular follow-up after treatment to assess:

• Local recurrence.

• Regional lymph node recurrence.

• Distant metastasis.

• Treatment-related complications.

Follow-up includes:

• Clinical examination.

• Assessment of nerve function.

• Imaging when clinically indicated.